Physician profile
Mark D Jackson
NPI 1023015005
$7,921.56
in general payments reported to CMS, 2019-2025
20 companies · $735 in 2025
The $735 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $274 · 2021: $2,451 · 2022: $714 · 2023: $1,265 · 2024: $1,861 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,667 · Travel and Lodging: $1,174 · Entertainment: $13.18 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,667.02 |
| Travel and Lodging | $1,173.84 |
| Entertainment | $13.18 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,888.12 | 2019-2025 | Air Optix, Total30, Dailies Total1 Multifocal |
| Johnson & Johnson Vision Care, INC. | $2,210.83 | 2019-2025 | Acuvue |
| Abbvie INC. | $502.26 | 2022-2025 | |
| Coopervision INC. | $456.02 | 2019-2024 | Misight Contact Lens |
| Maculogix, INC. | $342.44 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $277.41 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $253.22 | 2019-2024 | Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $219.83 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $142.71 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $138.21 | 2020 | |
| Kala Pharmaceuticals, INC. | $108.47 | 2021 | |
| Optovue, INC. | $66.67 | 2019 | |
| Oyster Point Pharma, INC. | $56.25 | 2022-2023 | Tyrvaya |
| Topcon Healthcare Solutions, INC. | $54.66 | 2019 | |
| Allergan, INC. | $49.24 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.89 | 2020-2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Optos, INC. | $32.63 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lombart Brothers, INC. | $18.66 | 2023 | Opd-III |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.